Bitterroot Bio has signed a multi-year research collaboration agreement with Biotheus to find innovative methods for modulating the immune system & inflammatory responses involved in the progression of various cardiovascular diseases
The partnership will combine Bitterroot Bio’s expertise in cardiovascular medicine & biology with Biotheus’ ability of protein therapeutics designing to discover & develop therapies for atherosclerosis and other cardiovascular diseases
The companies will conduct joint R&D to nominate product candidates for further development in preclinical & clinical programs
Ref: Globenewswire | Image: Biotheus
Related News:- Biotheus Collaborates with BioNTech for the Development and Commercialization of PM8002 to Treat Multiple Solid Tumor Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
